Canntab Therapeutics Limited reported earnings results for the third quarter and nine months ended February 28, 2023. For the third quarter, the company reported net loss was CAD 0.412628 million compared to CAD 0.418338 million a year ago. Basic loss per share from continuing operations was CAD 0.01 compared to CAD 0.01 a year ago.
For the nine months, net loss was CAD 1.91 million compared to CAD 2.24 million a year ago. Basic loss per share from continuing operations was CAD 0.05 compared to CAD 0.06 a year ago.